Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- rTMSIndependent statistical analysis of rTMS for the Treatment of Chronic Pain in GW1 Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01608321).
- rTMS Bimodal Treatment For Tinnitus: A Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of rTMS Bimodal Treatment For Tinnitus: A Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01590264).
- rTMS Combined With BWSTT in Stroke With Body Weight Supported Treadmill Training (BWSTT) After Stroke: Complete Statistical AnalysisIndependent statistical analysis of rTMS Combined With BWSTT in Stroke With Body Weight Supported Treadmill Training (BWSTT) After Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- rTMS to Enhance Cognitive Performance and Promote Resilience: Complete Statistical AnalysisIndependent statistical analysis of rTMS to Enhance Cognitive Performance and Promote Resilience: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04123496).
- RTSSIndependent statistical analysis of Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02992119).
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RuRaLIndependent statistical analysis of Hypocaloric Nutrition in Critically Ill Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01531335).
- Rural Home Hospital: Proof of Concept: Complete Statistical AnalysisIndependent statistical analysis of Rural Home Hospital: Proof of Concept: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04531280).
- Rural NDPPIndependent statistical analysis of The National Diabetes Prevention Program in Rural Communities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05387434).
- Rutgers Pilot for PREDICT- Patient LAB Test: Complete Statistical AnalysisIndependent statistical analysis of Rutgers Pilot for PREDICT- Patient LAB Test: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05607043).
- Ruxolitinib and Lenalidomide for Patients With Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib and Lenalidomide for Patients With Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01375140).
- Ruxolitinib for Adult T-Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib for Adult T-Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712659).
- Ruxolitinib for Cancer Cachexia: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib for Cancer Cachexia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04906746).
- Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ruxolitinib in Seborrheic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib in Seborrheic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05787860).
- RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03199872).
- RVD LiteIndependent statistical analysis of Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01782963).
- RVDDIndependent statistical analysis of Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- RYR1Independent statistical analysis of Antioxidant Therapy in RYR1-Related Congenital Myopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02362425).
- S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma: Complete Statistical AnalysisIndependent statistical analysis of S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006237).
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00088972).
- S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate…
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo: Complete Statistical AnalysisIndependent statistical analysis of S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- S0802 – Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib: primary endpoint results, effect estimate with…
- S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- S8PKIndependent statistical analysis of Safety and Performance of the Steroid-Releasing S8 Sinus Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01894503).
- S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma: Complete Statistical AnalysisIndependent statistical analysis of S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003590).
- SAABIndependent statistical analysis of Corticosteroid Pulse After Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00807586).
- SABRseqIndependent statistical analysis of Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study: Complete Statistical AnalysisIndependent statistical analysis of Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study: primary endpoint…
- SAD-PDIndependent statistical analysis of Study of Antidepressants in Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00086190).
- SAFEIndependent statistical analysis of Safe Administration of Flu Vaccine to Egg Allergic Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01264601).
- SAFEIndependent statistical analysis of Safety, Acceptability, and Feasibility of Enterade®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03782272).
- SAFERIndependent statistical analysis of Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA: Complete Statistical AnalysisIndependent statistical analysis of Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia: Complete Statistical AnalysisIndependent statistical analysis of Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS: Complete Statistical AnalysisIndependent statistical analysis of Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule: Complete Statistical AnalysisIndependent statistical analysis of Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection: Complete Statistical AnalysisIndependent statistical analysis of Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…